Antibody-DKKL1 Combination Therapy: A Potential Solution for Cancer Treatment

Target Name: DKKL1

NCBI ID: G27120

DKKL1

Antibody-DKKL1 Combination Therapy: A Potential Solution for Cancer Treatment

Cancer is a leading cause of death worldwide, with over 1.8 million new cases and 500,000 deaths in the United States alone in 2020. The development of new treatments for cancer has become a significant area of 鈥嬧?媟esearch and development in recent years. One approach to combatting cancer is to target the cancer cells with specific antibodies or drugs that can inhibit their growth and proliferation. In this article, we will focus on DKKL1 (Cancer/testis antigen 34), a protein that has been identified as a potential drug target for cancer.

DKKL1: Background and Characteristics

DKKL1, also known as cancer/testis antigen 34 (CTA34), is a human glycoprotein with a molecular weight of approximately 180 kDa. It is a type of transmembrane protein that is expressed in a variety of tissues, including the brain, heart, liver , and gastrointestinal tract. DKKL1 is highly glycosylated, which means that it has a high level of sugar molecules on its surface. This glycosylation state allows DKKL1 to have important biological functions in the body, such as participating in cell signaling and cell adhesion. , cell migration and immune response and other processes.

The relationship between DKKL1 and cancer

DKKL1 is expressed in a variety of cancers, including breast cancer, lung cancer, prostate cancer, and colorectal cancer. Studies have shown that DKKL1 is associated with cancer progression and invasiveness. The expression level of DKKL1 is inversely correlated with the survival rate of cancer patients, which means that DKKL1 may be a potential tumor biomarker.

Pharmacological significance of DKKL1

As a potential drug target, DKKL1 has broad application prospects. Research shows that inhibiting DKKL1 can significantly inhibit the growth and invasion of cancer cells. This is because DKKL1 plays a crucial signaling role in tumor cells and promotes the growth of tumor cells by regulating processes such as cell cycle, cell adhesion, and cell migration. At the same time, DKKL1 binds to the membrane receptors of tumor cells, causing the tumor cells to generate a series of signals, thereby further promoting their growth and invasion. Therefore, DKKL1 has become a potential tumor target.

Biological functions of DKKL1

DKKL1 has multiple biological functions in tumor cells. First, DKKL1 is a key molecule in the regulation of tumor cell cycle. Studies have found that DKKL1 can inhibit the G1 phase growth of tumor cells, leading to cell cycle arrest. In addition, DKKL1 can also inhibit the growth of tumor cells in the G2 phase and M phase, thereby inhibiting cell division.

Secondly, DKKL1 plays an important role in the adhesion and migration of tumor cells. Studies have shown that DKKL1 can interact with glycoproteins on the surface of tumor cells, thereby increasing the adhesion of tumor cells to the matrix. In addition, DKKL1 can also participate in the invasion and metastasis of tumor cells because it can reduce the adhesion ability of tumor cells to surrounding tissues.

Finally, DKKL1 plays an important role in the immunogenicity of tumor cells. Studies have shown that DKKL1 can promote the interaction between tumor cells and immune cells, thereby enhancing the immunogenicity of tumor cells. This role of DKKL1 helps tumor cells evade immune surveillance, thereby playing a key role in tumor growth and spread.

Clinical application prospects of DKKL1

As a potential tumor target, DKKL1 has broad application prospects in tumor treatment. Currently, several studies are exploring the use of antibody-DKKL1 combination therapy to treat various cancers. For example, using DKKL1 antibodies in combination with chemotherapy can significantly inhibit the growth of cancer cells, thereby improving patient survival rates. In addition, DKKL1 antibodies can be used to enhance the immunogenicity of tumors, thereby enhancing the patient's immune response to tumors.

Conclusion

DKKL1 as a

Protein Name: Dickkopf Like Acrosomal Protein 1

Functions: Involved in fertilization by facilitating sperm penetration of the zona pellucida. May promote spermatocyte apoptosis, thereby limiting sperm production. In adults, may reduce testosterone synthesis in Leydig cells. Is not essential either for development or fertility

The "DKKL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DKKL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets